10:45 a.m.

Coffee Break

11:00 a.m.

Introduction to potential targets

Mutagenesis and RNAi: Raul Andino

Capsid-binding compounds: Marc Collett

Exploiting dominant inhibition: Karla Kirkegaard

Protease inhibitors: Amy Patick

12:00 p.m.

Organization of afternoon breakout sessions

12:30 p.m.

Buffet Lunch

1:30 p.m.

Breakout sessions

3:30 p.m.

Coffee Break

3:45 p.m.

Reports on breakout sessions and discussion

5:30 p.m.


Wednesday, November 2, 2005

8:00 a.m.

Continental Breakfast

8:30 a.m.

Organization of day 2 breakout groups

9:00 a.m.

Working breakout group discussions

1. Public Health group: How would the drug be used in eradication? Who would patients be, how would they be identified and reached? What would be the advantages and disadvantages of the potential compounds identified in day 1 for different aspects of eradication?

2. Biology group: Evaluate each of the potential antivirals: how difficult would each be to develop, how likely to elicit resistance, how long would it take to develop, what would be its possible safety issues?

3. Development group: How much would each type of antiviral cost to develop? How hard might it be to move them

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement